learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
Search
forLearn
5 / 6 resultslearn Overview
learn Beta Polypeptide
learn Thymosin Beta 4
learn sh-Polypeptide-7
Research
5 / 1000+ results
research Recent European Legal Developments on Second Medical Uses and Dosage Regimes
European patent law now allows patents for new uses and dosages of known drugs, but protection scope is unclear.
research Generic Competition And Pharmaceutical Patent Strategies: A Sequel
The article concludes that recent legal rulings have strengthened the protection of pharmaceutical patents against generic competition.
research Court of Appeal Can Overrule Itself to Follow the EPO: UK Adopts EPO Stance on Second Medical Use Claims
The UK Court of Appeal ruled that new dosing regimens for drugs can be patented, aligning with the European Patent Office's approach.
research The Byzantine Logic of Patent Law Jurisprudence: Patent Protection for Dosage Regimes Revisited
UK courts and the European Patent Office are now more open to granting patents for new dosage regimes.
research Healthcare Innovation and Patent Law’s Pharmaceutical Privilege: Is There a Pharmaceutical Privilege? And If So, Should We Remove It?
The document suggests reevaluating the patent system to ensure public benefits from pharmaceutical privileges and to encourage more significant innovations.
Community Join
5 / 217 resultscommunity Phase II topical dut study - outperforms oral fin with a minor DHT reduction
Topical dutasteride 0.05% is more effective for hair growth than oral finasteride 1mg, with minimal DHT reduction. The formulation uses castor oil and MCTs for better absorption but is not widely available until 2028.
community Kintor Phase 2 Results released KX-826 (pyrilutamide)
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
community The EU has Finasteride and Dutasteride under review at risk of getting banned.
Finasteride and Dutasteride are under review in the EU due to concerns about side effects like depression, but they are unlikely to be banned. Access to these medications varies, with easier availability in the UK compared to some EU countries.
community Warning: Minoxidil usage around pets
Minoxidil is highly toxic to pets, especially cats and dogs, even in small amounts. Many users have switched to oral minoxidil to prevent accidental exposure to their pets.
community Possible Finasteride ban happening soon
Concerns about a potential finasteride ban in the EU, possibly affecting the US, are discussed. Users doubt a ban, citing its widespread use and suggest alternatives like minoxidil and dutasteride.